The abstract is read at the publisher; the summary is JClub's.
Immune effector cell-associated enterocolitis occurs in 3.0% of ciltacabtagene autoleucel recipients (39 of 1,308), with median onset at 75 days and 41% dying with active disease.
- Why it matters: IEC-EC is a delayed toxicity after BCMA-directed CAR T therapy, but its frequency, clinical course, and tissue features were not well characterized across centers to guide early management.
- What they did: A retrospective multicenter adjudication of 54 suspected cases from 8 institutions identified 41 IEC-EC cases (31 confirmed by anti-camelid variable heavy-chain immunohistochemistry, 10 probable) and assessed incidence, symptoms, biopsies, clonal T cells, and outcomes.
- The result: Duodenal biopsies showed villous blunting and cytotoxic T cell infiltrates even when upper endoscopy was normal (41%); dominant T cell clones appeared in 76%, and delayed neurotoxicity co-occurred in 41%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.